ATE498400T1 - Verwendung von ppar agonisten zur behandlung von herzversagen - Google Patents

Verwendung von ppar agonisten zur behandlung von herzversagen

Info

Publication number
ATE498400T1
ATE498400T1 AT05824351T AT05824351T ATE498400T1 AT E498400 T1 ATE498400 T1 AT E498400T1 AT 05824351 T AT05824351 T AT 05824351T AT 05824351 T AT05824351 T AT 05824351T AT E498400 T1 ATE498400 T1 AT E498400T1
Authority
AT
Austria
Prior art keywords
heart failure
ppar agonists
treat heart
treat
ppar
Prior art date
Application number
AT05824351T
Other languages
German (de)
English (en)
Inventor
Wolfgang Linz
Stefan Schaefer
Eugen Falk
Hans-Ludwig Schaefer
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of ATE498400T1 publication Critical patent/ATE498400T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT05824351T 2004-12-17 2005-12-06 Verwendung von ppar agonisten zur behandlung von herzversagen ATE498400T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04029946A EP1671633A1 (en) 2004-12-17 2004-12-17 Use of PPAR agonists for the treatment of congestive heart failure
PCT/EP2005/013046 WO2006063715A1 (en) 2004-12-17 2005-12-06 Use of ppar agonists for the treatment of congestive heart failure

Publications (1)

Publication Number Publication Date
ATE498400T1 true ATE498400T1 (de) 2011-03-15

Family

ID=34927823

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05824351T ATE498400T1 (de) 2004-12-17 2005-12-06 Verwendung von ppar agonisten zur behandlung von herzversagen

Country Status (16)

Country Link
US (1) US7601863B2 (enExample)
EP (2) EP1671633A1 (enExample)
JP (1) JP2008524129A (enExample)
KR (1) KR20070086332A (enExample)
CN (1) CN101072557A (enExample)
AR (1) AR051723A1 (enExample)
AT (1) ATE498400T1 (enExample)
AU (1) AU2005315920A1 (enExample)
BR (1) BRPI0519661A2 (enExample)
CA (1) CA2590391A1 (enExample)
DE (1) DE602005026443D1 (enExample)
IL (1) IL183810A0 (enExample)
MX (1) MX2007006678A (enExample)
MY (1) MY141010A (enExample)
TW (1) TW200635584A (enExample)
WO (1) WO2006063715A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399777B2 (en) 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
PL3523283T3 (pl) 2016-10-05 2021-12-13 Mitobridge, Inc. Postacie krystaliczne i postacie soli związków stanowiących agonistów ppar

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101070316A (zh) * 1999-04-28 2007-11-14 萨诺费-阿文蒂斯德国有限公司 作为ppar受体配体的二芳基酸衍生物
IL160556A0 (en) * 2001-08-31 2004-07-25 Aventis Pharma Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
WO2004082621A2 (en) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof
US6989462B2 (en) * 2003-03-25 2006-01-24 Sanofi-Aventis Deutschland Gmbh Synthesis of 2-chloromethyl-6-methylbenzoic ester
US6987118B2 (en) * 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators

Also Published As

Publication number Publication date
US7601863B2 (en) 2009-10-13
WO2006063715A1 (en) 2006-06-22
DE602005026443D1 (de) 2011-03-31
EP1827425B1 (en) 2011-02-16
EP1827425A1 (en) 2007-09-05
KR20070086332A (ko) 2007-08-27
AR051723A1 (es) 2007-01-31
TW200635584A (en) 2006-10-16
MX2007006678A (es) 2007-08-14
CN101072557A (zh) 2007-11-14
MY141010A (en) 2010-02-25
EP1671633A1 (en) 2006-06-21
US20080039512A1 (en) 2008-02-14
BRPI0519661A2 (pt) 2009-03-03
IL183810A0 (en) 2007-10-31
AU2005315920A1 (en) 2006-06-22
JP2008524129A (ja) 2008-07-10
CA2590391A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
EP2021352A4 (en) TREATMENT OF POOR FOLDING OF PROTEINS
EP2101785A4 (en) TREATMENT OF IT SEC
ATE534379T1 (de) Neue verwendung von peptid-verbindungen zur behandlung von muskelschmerzen
EP2182983A4 (en) TREATMENT OF AMYLOIDOGENIC DISEASES
ATE550329T1 (de) Heterobicyclische sulfonamidderivate zur behandlung von diabetes
ATE478864T1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE419856T1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE521352T1 (de) Verwendung von flibanserin zur behandlung von prämenopausalen störungen der sexuellen lust
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
EP1742675A4 (en) TREATMENT OF BIOMEDICAL WASTE
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE499105T1 (de) Behandlung oder vorbeugung von haut- oder gewebezuständen bei tieren unter verwendung von boryloxypyridylmethanonen
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
ATE438623T1 (de) Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
ATE510536T1 (de) Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
ATE493986T1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
EP1965827A4 (en) TREATMENT OF CONDITIONS RELATED TO DEMYELINATION
EP1924269A4 (en) VEGETATION WATER-BASED COMPOSITION FOR THE TREATMENT OF INFLAMMATORY CUTANEOUS DISEASES
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
ATE446092T1 (de) Verwendung von oxycodon zur behandlung von viszeralem schmerz
DE602006010449D1 (de) Behandlung von geflügel zwecks reduzierung der futon ascites
MX2009005550A (es) Inhibidores de fosfatasa de proteina tirosina para la promocion de la hipertrofia cardiaca fisiologica.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties